Allocate's interim results show good progress both strategically and financially. Strong deal flow since period-end and a good pipeline give us confidence in our full-year estimates into the typically much stronger H2. A 2015x P/E of 13.9x still looks to undervalue the company's platform for cross selling and improving quality of earnings.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here